Fate Therapeutics Inc (FATE): who owns it and who trades it
As of Nov 16, 2026, FATE insiders reported 7 open-market sales worth $336K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bahram Valamehr (CEO), with $168K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling FATE Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns FATE
156 funds and institutions reported FATE shares worth $195M at the end of Q2 2026, about 62% of the company. The largest holder is Redmile Group, LLC with 11.0%.
Funds and institutions (13F) 62%Everyone else 38%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Redmile Group, LLC | 12.87M | 11.04% | $34.8M | No change |
| BlackRock, Inc. | 7.30M | 6.26% | $19.7M | -28% |
| Vanguard Portfolio Management LLC | 4.55M | 3.90% | $12.3M | +10% |
| Vanguard Capital Management LLC | 4.45M | 3.81% | $12M | +6% |
| Acadian Asset Management LLC | 4.35M | 3.73% | $11.7M | +6% |
| AQR Capital Management LLC | 3.84M | 3.29% | $10.4M | +28% |
| Two Sigma Investments, LP | 3.59M | 3.08% | $9.7M | +4% |
| Johnson & Johnson | 3.38M | 2.90% | $9.1M | No change |
| Renaissance Technologies LLC | 2.98M | 2.56% | $8.1M | +0% |
| Millennium Management LLC | 2.43M | 2.09% | $6.6M | – |
| Goldman Sachs Group Inc | 2.05M | 1.76% | $5.5M | +54% |
| Geode Capital Management, LLC | 1.32M | 1.13% | $3.6M | -49% |
| T. Rowe Price Investment Management, Inc. | 1.08M | 0.93% | $2.9M | – |
| Jane Street Group, LLC | 1.03M | 0.88% | $2.8M | +59% |
| Citadel Advisors LLC | 993,308 | 0.85% | $2.7M | +5% |
| Bruce & Co., Inc. | 989,188 | 0.85% | $2.7M | +25% |
| Morgan Stanley | 694,580 | 0.60% | $1.9M | -10% |
| Vanguard Fiduciary Trust Co | 640,428 | 0.55% | $1.7M | -2% |
| Charles Schwab Investment Management Inc | 610,949 | 0.52% | $1.6M | -19% |
| Sixth Street Partners Management Company, L.P. | 610,949 | 0.52% | $1.6M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, FATE insiders reported $0 of open-market purchases and $336K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Kamal Adawi | CFO | Sale | 6,582 | $2.05 | $13.5K | Form 4 |
| Aug 4, 2026 | Cindy Tahl | See Remarks | Sale | 38,800 | $2.46 | $95.4K | Form 4 |
| Aug 4, 2026 | Bahram Valamehr | CEO | Sale | 43,947 | $2.46 | $108K | Form 4 |
| May 20, 2026 | Cindy Tahl | See Remarks | Sale | 25,590 | $1.88 | $48.1K | Form 4 |
| May 20, 2026 | Bahram Valamehr | CEO | Sale | 28,946 | $1.88 | $54.4K | Form 4 |
| Jan 9, 2026 | Cindy Tahl | See Remarks | Sale | 10,589 | $1.06 | $11.2K | Form 4 |
| Jan 9, 2026 | Bahram Valamehr | CEO | Sale | 5,190 | $1.07 | $5.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Bahram Valamehr | President and CEO, Director | – | $168K | Aug 4, 2026 |
| Cindy Tahl | See Remarks | – | $155K | Aug 4, 2026 |
| Kamal Adawi | Chief Financial Officer | – | $13.5K | Nov 3, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
FATE short interest
Moderate short interest. 8.2% of FATE shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went up 3%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 9.97M FATE shares were sold short, 8.2% of the shares outstanding, down 6.1% from the report before. At the average daily volume of 1.20M shares, buying them all back would take about 8.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 9.97M | 8.20% | -6% | 1.20M | 8.3 |
| Oct 15, 2026 | 10.62M | 8.86% | -1% | 1.22M | 8.7 |
| Sep 30, 2026 | 10.76M | 8.98% | +15% | 2.04M | 5.3 |
| Sep 15, 2026 | 9.39M | 7.83% | +3% | 893,769 | 10.5 |
| Aug 31, 2026 | 9.11M | 7.60% | +7% | 1.46M | 6.2 |
| Aug 14, 2026 | 8.51M | 7.10% | +11% | 2.59M | 3.3 |
| Jul 31, 2026 | 7.68M | 6.59% | +5% | 1.68M | 4.6 |
| Jul 15, 2026 | 7.32M | 6.28% | -2% | 3.69M | 2.0 |
| Jun 30, 2026 | 7.43M | 6.38% | -31% | 6.08M | 1.2 |
| Jun 15, 2026 | 10.82M | 9.28% | +1% | 3.62M | 3.0 |
| May 29, 2026 | 10.70M | 9.18% | +10% | 5.18M | 2.1 |
| May 15, 2026 | 9.73M | 8.35% | -5% | 4.91M | 2.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
FATE Therapeutics company events
FATE Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026AgreementFate Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share, having an aggregate… Filing
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 28, 2026AnnouncementThe California Institute for Regenerative Medicine awarded Fate Therapeutics, Inc. a $15 million grant to support the Company’s Phase 2 RECLAIM-LN clinical trial of FT819. Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 15, 2026LeadershipAs described below in Item 5.07 of this Current Report on Form 8-K, on June 12, 2026, the stockholders of Fate Therapeutics, Inc. approved a third amendment and restatement of the Company’s 2022 Stock Option and Incentive Plan (as so amended and restated, the “2022 A&R Plan”) to increase the… Filing
- Jun 4, 2026AnnouncementFate Therapeutics, Inc. updated its corporate presentation for use in meetings and at conferences, including at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress. Filing
- May 13, 2026ResultsReleased financial results. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
FATE Therapeutics financials
Famous investors that hold FATE
4 of the 50 well-known investors we track reported holding FATE in their latest 13F filing. The largest position is Jim Simons's, worth $5.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.37M | $5.6M | 0.0% | -20% |
| Israel Englander · Millennium Management | Q3 2026 | 2.17M | $5.1M | 0.0% | -11% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 846,920 | $2M | 0.0% | -15% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 209,501 | $497K | 0.0% | -53% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named FATE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 9, 2026 | Redmile Group, LLC | 13D/A | 15.0% |
| Nov 9, 2026 | Redmile Group, LLC | 13D/A | 15.0% |
Questions about Fate Therapeutics Inc (FATE) stock
Who owns the most FATE stock?
The largest reported owner of Fate Therapeutics Inc (FATE) is Redmile Group, LLC, with 11.0% of the company. In total, 156 funds and institutions reported holding FATE at the end of Q2 2026, together about 62% of the shares. See the largest owners.
Are FATE insiders buying or selling?
In the last 12 months, FATE insiders reported no open-market purchases and 7 sales worth $336K. The latest trade was on Nov 3, 2026. See every trade.
What is the short interest in FATE?
As of Oct 30, 2026, 9.97M FATE shares were sold short, 8.2% of the shares outstanding, down 6.1% from the report before. At the average daily volume of 1.20M shares, buying them all back would take about 8.3 trading days (days to cover). See the history.
Which famous investors hold FATE?
4 of the 50 well-known investors we track reported FATE in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $5.6M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.